Bolder BioTechnology, Inc. is a clinical stage protein therapeutics company organized around development of treatments that are easier for thepatient to use, safer, and more cost effective treatments. Typically, protein pharmaceuticals require frequent, often daily, dosing, typically by injection. The Bolder Biotecehnology Inc objective is therefore to address development of protein drugs not requiring frequent administration. Principals of the firm are using advanced protein engineering and targeted bioconjugation technologies to create longer-acting, more potent versions of existing FDA-approved protein pharmaceuticals (Enhanced Protein Therapeuticsâ¢) that can be administered less frequently, e.g., weekly to monthly, but with comparable or superior efficacy compared to currently marketed products. The firm's diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases
